Adaptive post-transcriptional reprogramming of metabolism limits response to targeted therapy in BRAF ^V600 melanoma

Abstract excerpt

Despite the success of therapies targeting oncogenes in cancer, clinical outcomes are limited by a residual disease that results in relapse. This residual disease is characterized by drug-induced adaptation, that in melanoma includes altered metabolism. Here, we examined how targeted therapy reprograms metabolism in BRAF-mutant melanoma cells using a genome-wide RNAi screen and global gene expression profiling. Th...

Topics

Open a Topic to create a Post that cites this publication.

• Drug Resistance, Neoplasm
• Melanoma
• Molecular Targeted Therapy
• Mutation
• Neoplasm Recurrence, Local
• Protein Kinase Inhibitors
• Proto-Oncogene Proteins B-raf
• RNA, Messenger

Identifiers and source

Literature Corpus work

f76e1a68-ce68-5ff1-8a0a-80f5477713e3

DOI

10.1101/626952